<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888468</url>
  </required_header>
  <id_info>
    <org_study_id>PB01</org_study_id>
    <nct_id>NCT04888468</nct_id>
  </id_info>
  <brief_title>Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents</brief_title>
  <official_title>A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Precision Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Precision Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in&#xD;
      patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of&#xD;
      pCAR-19B and phase II Recommended dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, single-arm, open-label study. The study plans to set up 3 dose&#xD;
      groups, adopting a dose-escalating 3+3 design, and plan to recruit about 9-18 subjects with&#xD;
      relapsed or refractory B-ALL.pCAR-19B will be infused to the subject by intravenous infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events after pCAR-19B infusion [Safety and Tolerability]</measure>
    <time_frame>28 days</time_frame>
    <description>Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Obtain the maximum tolerated dose of pCAR-19B cells[Safety and Tolerability]</measure>
    <time_frame>28 days</time_frame>
    <description>Dose-limiting toxicity after cell infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate after pCAR-19B infusion [Effectiveness]</measure>
    <time_frame>3 months</time_frame>
    <description>Objective response rate includes CR, CRi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCS of pCAR-19B cells [Cell dynamics]</measure>
    <time_frame>3 months</time_frame>
    <description>AUCS is defined as the area under the curve in 28 days and 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMAX of pCAR-19B cells [Cell dynamics]</measure>
    <time_frame>3 months</time_frame>
    <description>CMAX is defined as the highest concentration of pCAR-19B cells expanded in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMAX of pCAR-19B cells [Cell dynamics]</measure>
    <time_frame>3 months</time_frame>
    <description>TMAX is defined as the time to reach the highest concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of pCAR-19B cells[Cell dynamics]</measure>
    <time_frame>3 months</time_frame>
    <description>Cytokines such as hs-CRP, IL-6 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of pCAR-19B cells</measure>
    <time_frame>3 months</time_frame>
    <description>Anti-CAR antibody</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Relapsed Pediatric ALL</condition>
  <condition>Refractory Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>pCAR-19B cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of pCAR-19B cells by dose-escalating</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pCAR-19B cells</intervention_name>
    <description>Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.</description>
    <arm_group_label>pCAR-19B cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with B-ALL，and meet one of the following conditions:&#xD;
&#xD;
               1. First-line or multiple-line salvage chemotherapy did not achieve complete&#xD;
                  remission；&#xD;
&#xD;
               2. Early relapse after complete remission (&lt;12 months), or late relapse after&#xD;
                  complete remission (≥12 months) and complete remission has not been achieved&#xD;
                  after 1 course of treatment；&#xD;
&#xD;
               3. Relapse after autologous or allogeneic hematopoietic stem cell transplantation;&#xD;
&#xD;
          2. Ph+ALL patients should also receive at least two TKI treatments；&#xD;
&#xD;
          3. For allogeneic hematopoietic stem cell transplant subjects, the following conditions&#xD;
             must be met：&#xD;
&#xD;
               1. Allo-HSCT takes ≥6 months before pCAR-19B infusion；&#xD;
&#xD;
               2. No GVHD of grade 2 or above occurred within 2 weeks before PBMC collection;&#xD;
&#xD;
          4. Express CD19;&#xD;
&#xD;
          5. 3~21 years old, no gender limit;&#xD;
&#xD;
          6. The expected survival time is more than 12 weeks;&#xD;
&#xD;
          7. KPS&gt;60;&#xD;
&#xD;
          8. No serious mental disorders;&#xD;
&#xD;
          9. The function of important organs is basically normal:&#xD;
&#xD;
               1. Heart function: echocardiography indicates that the cardiac ejection fraction is&#xD;
                  ≥50%, and the electrocardiogram has no obvious abnormalities;&#xD;
&#xD;
               2. Renal function: serum creatinine≤2.0×ULN;&#xD;
&#xD;
               3. Liver function: ALT and AST ≤5×ULN;&#xD;
&#xD;
               4. Total bilirubin and alkaline phosphatase≤3×ULN ;&#xD;
&#xD;
               5. Blood oxygen saturation&gt;92%.&#xD;
&#xD;
         10. Have standards for apheresis or venous blood collection, and no other cell collection&#xD;
             contraindications;&#xD;
&#xD;
         11. The patient himself or his guardian agrees to participate in the clinical trial and&#xD;
             signs the ICF, indicating that he understands the purpose and procedures of the&#xD;
             clinical trial and is willing to participate in the research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With central nervous system disease at the time of screening;&#xD;
&#xD;
          2. Have received CAR-T therapy or other genetically modified cell therapy;&#xD;
&#xD;
          3. Participated in other clinical studies within 1 month before screening;&#xD;
&#xD;
          4. Have received the following anti-tumor treatments before screening: received&#xD;
             chemotherapy, targeted therapy or other experimental drug treatments within 14 days or&#xD;
             at least 5 half-lives (whichever is shorter);&#xD;
&#xD;
          5. Have received a live attenuated vaccine within 4 weeks before screening;&#xD;
&#xD;
          6. Cerebrovascular accident or seizure occurred within 6 months before signing the ICF;&#xD;
&#xD;
          7. Suffered from any of the following heart diseases:&#xD;
&#xD;
               1. NYHA stage III or IV congestive heart failure;&#xD;
&#xD;
               2. Myocardial infarction or CABG occurred ≤6 months before enrollment;&#xD;
&#xD;
               3. Clinically significant ventricular arrhythmia, or history of unexplained syncope&#xD;
                  (except for cases caused by vasovagal or dehydration);&#xD;
&#xD;
               4. History of severe non-ischemic cardiomyopathy.&#xD;
&#xD;
          8. Uncontrollable infection in the 2 weeks before screening；&#xD;
&#xD;
          9. Active autoimmune diseases；&#xD;
&#xD;
         10. Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years&#xD;
             before screening, except for fully treated cervical carcinoma in situ, basal cell or&#xD;
             squamous cell skin cancer, local prostate cancer after radical resection, and duct in&#xD;
             situ after radical resection cancer；&#xD;
&#xD;
         11. HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is&#xD;
             positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis&#xD;
             positive; CMV DNA positive;&#xD;
&#xD;
         12. Women who are pregnant or breastfeeding, and male or female subjects who plan to have&#xD;
             children within 1 year after receiving pCAR-19B cell reinfusion;&#xD;
&#xD;
         13. Other situations considered by the researcher to be unsuitable to participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianfeng Zhou, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenya Hong, M.D</last_name>
    <phone>86-27-63639810</phone>
    <email>hongzhenya@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Di Wang, M.D</last_name>
    <phone>86-27-83665027</phone>
    <email>dicky_wang@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenya Hong, M.D</last_name>
      <phone>86-27-63639810</phone>
      <email>hongzhenya@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Di Wang, M.D</last_name>
      <phone>86-27-83665027</phone>
      <email>dicky_wang@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jianfeng zhou, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenya Hong, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Di Wang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liang Huang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR-T</keyword>
  <keyword>CD19</keyword>
  <keyword>B-ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

